News
Media Contact
Thomas Schneckenburger
thomas.schneckenburger@molecularpartners.com
Tel: +41 44 755 5728
International Media Contact
Lisa Raffensperger
lisa@tenbridgecommunications.com
Tel: +1 617 903 8783
Publications
The scientific background of the DARPin® technology has been summarized in various reviews. For further information, please see below, or contact us.
- Azaro, A. et al. (2018), Journal of Clinical Oncology 36: 2520-2520.
- Rao, L. et al. (2018), Oncotarget 9: 13366-13381.
- Fiedler, U. et al. (2017), Oncotarget 8: 98371-98383.
- Binz, H.K. et al. (2017), MAbs 9: 1262-1269.
- Baird, R. et al. (2018), A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors. Cancer Research.
- Fiedler, U. et al. (2017), Pre-clinical antitumor activity, tumor localization, and pharmacokinetics of MP0274, an apoptosis inducing, biparatopic HER2-targeting DARPin®. Cancer Research.
- Link, A. et al. (2018), Preclinical pharmacology of MP0310. Cancer Research.
- Souied, E. et al. (2014), Phase I of Abicipar in wet AMD. Am. J. Ophthalmol.
- Campochiaro, P.A. et al. (2013), Phase I of Abicipar in DME. Am. J. Ophthalmol.Stumpp, M.T. et al. (2007), DARPins Review. Curr. Opin. Drug. Discov. Devel. 10:153-159.
- Binz, H. K. et al. (2005), DARPins Review. Nat. Biotechnol. 23: 1257-1268.
- Dong, R. et al. (2013). HuR: a promising therapeutic target for angiogenesis. Angiogenisis.
- Martin, S.A. et al (2010). Mismatch Repair Therapeutic Targeting of the DNA Mismatch Repair Pathway. Clin Cancer Res.
- Jost, C. et al. (2013). Structural Basis for Eliciting a Cytotoxic Effect in HER2-Overexpressing Cancer Cells via Binding to the Extracellular Domain of HER2. Structure.
